MIRASOL Phase 3 trial

December 17, 2019January 21, 2020

Pivotal Trial of Mirvetuximab Soravtansine in Advanced Ovarian Cancer Levels Likely in 2020

News

ImmunoGen is planning to open an open-label, pivotal clinical trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer patients with high levels of the folate receptor alpha (FRα) protein early next year, ... Read more

October 7, 2019October 7, 2019

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

News

ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to ... Read more